Ernexa Therapeutics Stock Soars 30% on Positive Preclinical Cancer Drug Data

Ernexa Therapeutics (NASDAQ:ERNA) shares jumped by as much as 30% on Wednesday after the biotechnology firm announced positive preclinical data for its lead cell therapy candidate, ERNA-101. The results, which were reproduced and validated by an independent research organization, showed significant efficacy in treating ovarian cancer in animal models.

Key Study Findings

The company reported that an independent contract research organization successfully replicated earlier findings from The University of Texas Anderson Cancer Center. The new, larger study demonstrated that the combination of ERNA-101 with an anti-PD-1 therapy produced a strong therapeutic response.

Key results from the preclinical trial include:

• 67% of treated animals (10 out of 15) achieved complete tumor clearance and long-term survival.
• In contrast, no complete tumor clearance or durable survival was observed in the 45 animals in control groups, which received either ERNA-101 alone, anti-PD-1 therapy alone, or no treatment.

Path to Human Trials

Ad

This third-party validation is a critical milestone for Ernexa as it advances ERNA-101 toward clinical development. The positive data supports the company's plan to submit an Investigational New Drug (IND) application to regulators in the third quarter of 2026.

Following the IND submission, Ernexa anticipates initiating a first-in-human Phase 1 clinical trial in the fourth quarter of 2026. For investors, the progression from preclinical to clinical stages often represents a significant de-risking event in a drug's development lifecycle.

The Science Behind ERNA-101

ERNA-101 is a cell therapy designed to treat advanced cancers. According to the company, the therapy works by selectively homing to ovarian tumors and delivering an engineered cytokine directly into the tumor microenvironment. This localized delivery is designed to activate the immune system and increase the infiltration of cancer-fighting T cells into tumors that are typically difficult for the immune system to detect.

The study was conducted in an immunocompetent syngeneic ovarian cancer model, with treatment response monitored via bioluminescence imaging to confirm tumor clearance.